Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients

Launched by SAMSUN UNIVERSITY · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how adding albumin, a protein found in blood, affects the delivery of oxygen to patients with sepsis who are in the intensive care unit (ICU). Sepsis is a serious condition that occurs when the body has a severe response to an infection, and providing the right fluids is crucial for treatment. While current guidelines recommend using balanced fluids for patients with sepsis, this study aims to explore whether using albumin can further improve oxygen delivery, which is vital for recovery.

To participate in this trial, individuals need to be over 18 years old and have been diagnosed with sepsis. Specifically, they should have low albumin levels after receiving a significant amount of fluid treatment (more than 4 liters a day) and require albumin replacement. However, patients who are pregnant, have certain heart or blood circulation issues, or have died within the first 24 hours of ICU admission are not eligible. If you or a loved one qualify for this trial, the study will help determine if albumin can enhance care for sepsis patients and improve their chances of recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Followed up with a diagnosis of sepsis,
• • over 18 years old
• • Patients who were diagnosed with hypo-albuminemia after more than 4L/day fluid resuscitation and underwent albumin replacement
• Exclusion Criteria:
• • Consent is not given by the patient or his/her guardian,
• • The initial cause of shock was hypovolemic, cardiogenic or obstructive shock.
• • Pregnancy or suspected pregnancy
• • Peripheral limb or severe organ ischemia with peripheral artery disease
• • Cardiac functions cannot be evaluated optimally by transthoracic echocardiography
• • Patients who died within the first 24 hours after intensive care admission